Mastocytosis demystified.

Area of Science:

• Hematology
• Oncology
• Rare Diseases

Background:

• Mastocytosis is a rare clonal hematological neoplasm characterized by mast cell accumulation.
• The KIT D816V mutation is present in over 95% of patients, driving disease pathogenesis.
• Clinical heterogeneity arises from mast cell mediator release and potential end-organ damage.

Approach:

• This review synthesizes current knowledge on mastocytosis diagnosis and classification.
• It evaluates established diagnostic criteria and clinical staging systems.
• Therapeutic strategies for nonadvanced and advanced systemic mastocytosis are assessed.

Key Points:

• Accurate diagnosis and classification are crucial for personalized therapy in systemic mastocytosis.
• The KIT D816V mutation is a key molecular driver.
• Variable manifestations range from mediator release symptoms to end-organ damage.

Conclusions:

• This review provides an overview of diagnostic criteria, classification, and risk stratification for systemic mastocytosis.
• It highlights current therapeutic options for adult patients with nonadvanced and advanced disease.
• Personalized treatment strategies are essential for managing this complex hematological neoplasm.